KetamineOne Capital has announced that it is entering into a collaborative partnership with Cognetivity Neurosciences Ltd (CSE:CGN, OTCQB:CGNSF) to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
In the initial stage of the partnership, both companies will partner on two separate clinical studies -- one for depression and the second for PTSD.
KetamineOne said the protocols for both studies have received Institutional Review Board (IRB) approval and patient recruitment is expected to occur in early 2022. KetamineOne’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.
READ: KetamineOne plans inaugural research studies targeting depression and post-traumatic stress disorder
KetamineOne is dedicated to building the critical infrastructure needed to provide potentially breakthrough and life-changing treatments for conditions such as anxiety, PTSD, chronic pain, and addiction via ketamine-assisted therapy and psychedelic medicines.
Cognetivity’s Integrated Cognitive Assessment (ICA) technology has already been deployed throughout KetamineOne’s network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.
KetamineOne said the clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool. It has already been widely deployed in clinical care from North America and the Middle East to clinics in the UK’s National Health Service.
The project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities -- not only on a stand-alone basis but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.
It is well documented that there is vast potential for improvement in the treatment of such conditions. According to the World Health Organization, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases -- more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy US$16 trillion in economic output between 2011 and 2030.
KetamineOne said the global market for PTSD therapeutics is expected to reach US$3.1 billion by 2027, with the global market for the treatment of anxiety disorders and depression predicted to exceed US$13 billion by the same year.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham